Equities research analysts expect that Kalvista Pharmaceuticals Inc (NASDAQ:KALV) will report ($0.56) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Kalvista Pharmaceuticals’ earnings, with estimates ranging from ($0.62) to ($0.49). Kalvista Pharmaceuticals reported earnings per share of ($0.49) during the same quarter last year, which suggests a negative year over year growth rate of 14.3%. The firm is scheduled to issue its next quarterly earnings results on Friday, March 15th.
According to Zacks, analysts expect that Kalvista Pharmaceuticals will report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.11) to ($1.66). For the next year, analysts anticipate that the firm will report earnings of ($3.02) per share, with EPS estimates ranging from ($4.21) to ($1.83). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Kalvista Pharmaceuticals.
Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Friday, December 14th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.24. The company had revenue of $5.59 million during the quarter, compared to the consensus estimate of $3.70 million. Kalvista Pharmaceuticals had a negative return on equity of 29.46% and a negative net margin of 84.47%.
Several research analysts have weighed in on the company. BidaskClub downgraded Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 18th. Cantor Fitzgerald set a $32.00 price target on Kalvista Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 3rd. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. Jefferies Financial Group assumed coverage on Kalvista Pharmaceuticals in a report on Tuesday, October 30th. They issued a “buy” rating and a $30.00 price target for the company. Finally, TheStreet upgraded Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Thursday, December 20th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $26.00.
In other news, insider Christopher Yea sold 1,902 shares of the business’s stock in a transaction on Wednesday, January 23rd. The shares were sold at an average price of $17.01, for a total transaction of $32,353.02. Following the completion of the sale, the insider now directly owns 84,271 shares of the company’s stock, valued at approximately $1,433,449.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Edward P. Feener sold 4,000 shares of the business’s stock in a transaction on Wednesday, January 16th. The shares were sold at an average price of $19.55, for a total transaction of $78,200.00. Following the sale, the insider now directly owns 106,334 shares of the company’s stock, valued at $2,078,829.70. The disclosure for this sale can be found here. Insiders have sold a total of 51,689 shares of company stock valued at $1,020,823 over the last three months. Corporate insiders own 38.40% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in KALV. VHCP Management III LLC purchased a new stake in shares of Kalvista Pharmaceuticals during the 3rd quarter valued at $28,410,000. Vivo Capital LLC grew its stake in shares of Kalvista Pharmaceuticals by 352.6% during the 3rd quarter. Vivo Capital LLC now owns 1,359,149 shares of the specialty pharmaceutical company’s stock valued at $30,051,000 after buying an additional 1,058,824 shares during the period. VHCP Management II LLC purchased a new stake in shares of Kalvista Pharmaceuticals during the 3rd quarter valued at $16,785,000. Vanguard Group Inc grew its stake in shares of Kalvista Pharmaceuticals by 152.4% during the 3rd quarter. Vanguard Group Inc now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after buying an additional 179,092 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Kalvista Pharmaceuticals by 152.4% during the 3rd quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after buying an additional 179,092 shares during the period. 72.95% of the stock is owned by institutional investors.
Shares of KALV opened at $16.94 on Tuesday. The firm has a market capitalization of $284.40 million, a price-to-earnings ratio of -11.07 and a beta of 2.74. Kalvista Pharmaceuticals has a fifty-two week low of $7.73 and a fifty-two week high of $25.57.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Recommended Story: Retained Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.